Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2003
03/20/2003WO2003000195A3 Method and material for treating immune diseases
03/20/2003WO2002102808A3 (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR
03/20/2003WO2002099075A3 Prmts as modifiers of the p53 pathway and methods of use
03/20/2003WO2002096366A3 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
03/20/2003WO2002094342A3 Compositions for protein delivery via the pulmonary route
03/20/2003WO2002091993A3 Estrogen receptor modulators
03/20/2003WO2002087556A9 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
03/20/2003WO2002087424A3 Treatment and diagnosis of macrophage mediated disease
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002074758A3 Novel amines as histamine-3 receptor ligands and their therapeutic applications
03/20/2003WO2002072602A3 Somatostatin antagonists
03/20/2003WO2002050255A3 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
03/20/2003WO2002038726A3 Paramyxovirus vector for gene transfer to the cardiovascular system
03/20/2003WO2002032412A3 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
03/20/2003WO2002022211A3 Reduction of the electrocardiographic ot interval
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003WO2002004490A3 Lipid metabolism molecules
03/20/2003US20030055307 Devices for detection and therapy of atheromatous plaque
03/20/2003US20030055286 Il-8 receptor antagonists
03/20/2003US20030055275 Prevention of neutrophil recruitment
03/20/2003US20030055265 Oxazole derivatives
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055258 New crystal modification of torasemide
03/20/2003US20030055250 Pteridine compounds for the treatment of psoriasis
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055246 Serine protease inhibitors
03/20/2003US20030055245 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof
03/20/2003US20030055244 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
03/20/2003US20030055236 Secreted protein HKABT24
03/20/2003US20030055227 Process for obtaining lignan
03/20/2003US20030055097 Indazolyl-substituted pyrroline compounds as kinase inhibitors
03/20/2003US20030055095 Administering to the patient a therapeutically effective amount of a compound that is an MEK inhibitor for inhibiting neutrophil migration
03/20/2003US20030055093 For therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction
03/20/2003US20030055091 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
03/20/2003US20030055088 Aryl substituted pyridines and the use thereof
03/20/2003US20030055086 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
03/20/2003US20030055074 For use in therapy of psychic and neurological disorders
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055062 Heteroaryl urea neuropeptide Y Y5 receptor antagonists
03/20/2003US20030055061 Therapy of disease or condition which is caused by a disorder of the serotonin system by administering 2,7-substituted octahydro-1H-pyrido(1,2-a)pyrazine derivatives, and their acid addition salts
03/20/2003US20030055060 Imidazo-triazine derivatives as ligands for GABA receptors
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055048 Compositions and methods for treating or preventing convulsions or seizures
03/20/2003US20030055046 Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055035 Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions
03/20/2003US20030055032 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
03/20/2003US20030055031 As anticonvulsants; for therapy and prophylaxis of ischaemias, anoxia, neurodegenerative diseases
03/20/2003US20030055027 For therapy of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites
03/20/2003US20030055024 Administering in divided doses an effective amount of a vascular damaging agent or a pharmaceutically acceptable salt thereof for production of a vascular damaging effect in a warm-blooded animal such as a human
03/20/2003US20030055021 Compounds for the treatment of ischemia
03/20/2003US20030055019 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
03/20/2003US20030055014 Administering at least one antiangiogenic nucleic acid molecule in an amount effective to inhibit angiogenesis
03/20/2003US20030055006 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use
03/20/2003US20030055004 GPE analogs and peptidominetics
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054996 Contacting complex comprising a GRP94 protein with a binding agent that is immobilized to a solid phase support, to immobilize the complex to solid phase support; collecting the remaining sample; eluting the complex from solid phase support
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054973 Methods and compositions for the repair and/or regeneration of damaged myocardium
03/20/2003US20030054492 Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
03/20/2003US20030054445 Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
03/20/2003US20030054409 Novel complex-forming proteins
03/20/2003US20030054398 Isolated human aminotransferase proteins, nucleic acid molecules encoding aminotransferase proteins and uses thereof
03/20/2003US20030054058 Vitex agnus castus extract
03/20/2003US20030054046 Hydrated dressing containing metal microbiocide
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054014 Administering fungi spores; aging resistance
03/20/2003US20030053989 Administering nucleic acid
03/20/2003US20030053981 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
03/20/2003US20030053958 For treating pulmonary hypertension; sustained release; has no effect on heart rate
03/20/2003US20030053953 Wherein void comprises vapor of volatile liquid (aliphatic hydrocarbons, chlorofluorocarbons, tetraalkyl silanes, and perfluorocarbons); for computed tomography imaging of the gastrointestinal region
03/20/2003CA2806723A1 Synthetic heparin pentasaccharides
03/20/2003CA2806604A1 Synthetic heparin pentasaccharides
03/20/2003CA2806561A1 Synthetic heparin pentasaccharides
03/20/2003CA2460348A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003CA2460190A1 Transdermal administration of an enalapril ester
03/20/2003CA2460117A1 Expression profiling in the intact human heart
03/20/2003CA2459973A1 Carbazole derivatives and their use as npy5 receptor antagonists
03/20/2003CA2459945A1 Methods of screening molecules that are used to prevent cardiovascular diseases
03/20/2003CA2459890A1 Crystal structure of baff, and use thereof in drug design
03/20/2003CA2459882A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003CA2459533A1 Methods of treating pulmonary disease
03/20/2003CA2459531A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003CA2459527A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003CA2459515A1 Indole derivatives
03/20/2003CA2459445A1 Benzothiepine ileal bile acid transport inhibitors
03/20/2003CA2459120A1 Human tissue urokinase type plasminogen activator formulation
03/20/2003CA2458029A1 Methods of treating cytokine mediated diseases
03/20/2003CA2455990A1 Methods for diagnosing and treating diseases and conditions associated with protein kinase c.lambda.
03/20/2003CA2452194A1 Sustained release pharmaceutical compositions comprising a silicone support material
03/20/2003CA2451454A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/19/2003EP1293511A1 Canine liver cell growth factor
03/19/2003EP1293510A1 Novel polypeptide and its dna
03/19/2003EP1293503A1 Triazole derivatives
03/19/2003EP1293196A2 Pharmaceutical composition comprising doxazosin
03/19/2003EP1292683A2 Secreted redox proteins
03/19/2003EP1292681A1 Antigenic polypeptides
03/19/2003EP1292680A2 Agonist anti-trk-c monoclonal antibodies
1 ... 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 ... 1595